Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and is designed to enroll up to 39 patients. Participants will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, targeting those who have progressed on or are ineligible for current standard-of-care therapies.
This clearance marks a significant milestone for Lantern Pharma as it expands its clinical development into Europe and validates its AI-driven precision oncology strategy. The trial leverages the company's proprietary RADR platform to identify patients most likely to benefit from LP-184, potentially improving outcomes and reducing trial costs. The decision by the EMA underscores the growing acceptance of biomarker-guided approaches in oncology and opens the door for further European expansion of Lantern's pipeline.
LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. Additionally, Lantern's pipeline includes LP-284, targeting hematologic and solid tumors, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. The company's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream.
The announcement carries implications for patients with limited treatment options, as bladder cancer remains a challenging disease with high recurrence rates. By focusing on a biomarker-defined subgroup, the trial aims to deliver a more targeted therapy, potentially improving efficacy and reducing side effects. For investors, the EMA clearance signals regulatory progress and de-risks the clinical program, while the expansion into Europe broadens the potential market for LP-184. Lantern's use of AI to streamline drug development could also set a precedent for other precision oncology companies.
The full press release is available at https://ibn.fm/6ku4F. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.
